ArticleBMC cancer2007
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.
Article in BMC cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
148 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trials.Saudi medical journal · 2017Pooled it
- Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy.World journal of surgical oncology · 2014Pooled it
- Pooled it
- Evaluation of the TCGA-Surrogate (ProMisE) Molecular Classification and Clinical Features of Endometrial Carcinoma: A Study of 97 Cases from China.International journal of women's health · 2026Article
- Angiovolume and Peak Enhancement on Preoperative CAD-Derived MRI as Prognostic Factors in Primary Operable Triple-Negative Breast Cancer.Tomography (Ann Arbor, Mich.) · 2025Article
- Role of PARP Inhibitors: A New Hope for Breast Cancer Therapy.International journal of molecular sciences · 2025Review
- Prioritizing drug targets by perturbing biological network response functions.PLoS computational biology · 2024Article
- Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer.Genome medicine · 2024Article
- Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.European journal of cancer (Oxford, England : 1990) · 2023Article
- Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis.Diagnostics (Basel, Switzerland) · 2023Article
- Prognostic factors for cancer-specific survival in 220 patients with breast cancer: A single center experience.Cancer reports (Hoboken, N.J.) · 2023Article
- Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation.Medicina (Kaunas, Lithuania) · 2022Article
- Application value of conventional ultrasound combined with shear wave elastography in diagnosing triple negative breast cancer.Gland surgery · 2021Article
- Study of the Genetic Variants inCancers · 2021Article
- Development of new brain metastases in triple negative breast cancer.Journal of neuro-oncology · 2021Article
- The Biological Function of TUSC7/miR-1224-3p Axis in Triple-Negative Breast Cancer.Cancer management and research · 2021Article
- Molecular classification predicts survival for breast cancer patients in Vietnam: a single institutional retrospective analysis.International journal of clinical and experimental pathology · 2021Article
- Breast Trauma and Triple-Negative Hemorrhagic Cystic Carcinoma: Management and Treatment.The American journal of case reports · 2020Article
- Biological and clinical significance of flap endonuclease‑1 in triple‑negative breast cancer: Support of metastasis and a poor prognosis.Oncology reports · 2020Article
- Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
88 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBasal-like breast cancer has been extensively characterized on the basis of gene expression profiles, but it is becoming increasingly common for these tumors to be defined on the basis of immunohistochemical (IHC) staining patterns, particularly in retrospective studies where material for expression profiling may not be available. The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested.
methodsUsing datasets from two different hospitals we describe how using different combinations of immunohistochemical patterns has different effects on estimating prognosis at different time intervals after diagnosis. As our baseline, we used two IHC patterns ER-/PR-/HER2-("triple negative phenotype", TNP) and ER-/HER2-/CK5/6+ and/or EGFR+ ("core basal phenotype", CBP).
resultsThere was no overall difference in survival between the two hospital-based series, but there was a difference between the TNP and non-TNP groups which was most marked at 3 years (76.8% vs 93.5%, p < .0001). This difference reduced with time, suggesting that long term survivors (beyond 10 years) in the TNP group may have comparable survival to non-TNP cases. A similar difference was seen if CBP was used instead of TNP. However when CK5/6 and/or EGFR expressing tumors were analyzed without consideration of ER/PR status, the reduction in survival increased with time, becoming more pronounced at 10 years than at 3 years.
conclusionOur findings suggests that CK5/6 and/or EGFR expressing tumor types have a persistently poorer prognosis over the longer term, an observation that may have important therapeutic implications as drugs that target the EGFR are currently being evaluated in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.